Dan Cohen

Is There a Role for [18F]FDG PET-CT in Staging MALT Lymphoma?

I. Avivi, E. Even-Sapir, Y. Herishanu, 2022, Cancers.

[18F]FDG PET-CT in patients with DLBCL treated with CAR-T cell therapy: a practical approach of reporting pre- and post-treatment studies

I. Avivi, E. Even-Sapir, R. Ram, 2021, European Journal of Nuclear Medicine and Molecular Imaging.

Lymphoma pseudoprogression observed on [18F]FDG PET-CT scan 15 days after CAR-T infusion

E. Even-Sapir, C. Perry, O. Beyar-Katz, 2022, European Journal of Nuclear Medicine and Molecular Imaging.

Staging Prostate Cancer with 68Ga-PSMA-11 PET/CT in the Elderly: Is Preimaging Biopsy Imperative?

E. Even-Sapir, O. Yossepowitch, D. Keizman, 2023, The Journal of Nuclear Medicine.

PET radiotracers for whole-body in vivo molecular imaging of prostatic neuroendocrine malignancies

E. Even-Sapir, Mikhail Kesler, Ibrahim Fahoum, 2023, European Radiology.

Beyond Visual Assessment of Basal Ganglia Uptake: Can Automated Method and Pineal Body Uptake Assessment Improve Identification of Nigrostriatal Dysfunction on 18F-DOPA PET/CT?

E. Even-Sapir, H. Lerman, Dan Cohen, 2023, International journal of molecular sciences.

A lesson in humility: the added values of PET-MRI over PET-CT in detecting malignant hepatic lesions

E. Even-Sapir, Mikhail Kesler, C. Levine, 2023, European Journal of Nuclear Medicine and Molecular Imaging.